Author name: Morgan Tuttle

Cure SMA to Host Webinar on Treatment Access and Clinical Trials on February 15

Leave a Comment / Clinical Trials, Community Awareness, Front Page News /

On Thursday, February 15, at 12:00pm CST (10:00am PST/11:00am MST/1:00pm EST), Cure SMA will hold a webinar updating the community on treatment access and clinical trials. Among the topics covered will be:  The current status of Spinraza access, including dosing, sites, and insurance Updates on ongoing clinical trials Updates on upcoming clinical trials News from […]

Cure SMA to Host Webinar on Treatment Access and Clinical Trials on February 15 Read More »

SMA Industry Collaboration Releases Spinal Muscular Atrophy Voice of the Patient (VoP) Report

Leave a Comment / Advocacy, Front Page News, Our Impact, Research /

Cure SMA and our partners in the SMA Industry Collaboration are pleased to announce the release of the Spinal Muscular Atrophy Voice of the Patient (VoP) Report. This report is a thorough written account of the Patient-Focused Drug Development (PFDD) Meeting with the FDA, in the spring of 2017. Patient Focused Drug Development Meeting with

SMA Industry Collaboration Releases Spinal Muscular Atrophy Voice of the Patient (VoP) Report Read More »

2018 Updated SMA Drug Pipeline Released

Leave a Comment / Clinical Trials, Front Page News, Research /

We’ve recently released an update to the SMA drug pipeline. This latest version includes: 16 active programs, including one approved therapy.  14 pharmaceutical partners. 6 programs in clinical trials. An ever-increasing breadth of potential treatment approaches to SMA. Effective Treatments for All Ages, Stages and Types of SMA In December 2016, our community celebrated the approval

2018 Updated SMA Drug Pipeline Released Read More »

AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy

Leave a Comment / Clinical Trials, Research /

AveXis, a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today provided an overview of the expanded clinical development program for the company’s initial gene therapy candidate, AVXS-101, for the treatment of spinal muscular atrophy (SMA). In addition to the ongoing pivotal trial in SMA Type 1

AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy Read More »

Scholar Rock Announces Plan to Bring Possible SMA Treatment into Clinical Trials

Leave a Comment / Clinical Trials, Front Page News, Research /

Scholar Rock, a biotechnology company based in Boston, has announced that they will be investing nearly $50 million to bring SRK-015, a muscle drug for possible treatment of SMA, into human clinical trials. SRK-015 is Scholar Rock’s lead clinical candidate. They expect to start clinical development in the first half of 2018, although timelines for

Scholar Rock Announces Plan to Bring Possible SMA Treatment into Clinical Trials Read More »

Cure SMA Launches Advocacy Action Network

Leave a Comment / Advocacy, Front Page News, Our Impact /

Working together, we’ve achieved tremendous success in advocating for ourselves, our families, and our whole community, particularly in the past few years. Today, we’re building on this momentum with the launch of our Advocacy Action Network. The Advocacy Action Network will allow our advocates to share their voices on issues that impact our community, including research

Cure SMA Launches Advocacy Action Network Read More »

Minnesota Becomes Second State to Adopt Newborn Screening for SMA

Leave a Comment / Advocacy, Front Page News, Our Impact /

On December 27, the Minnesota Commissioner of Health accepted the recommendation of the state’s Advisory Committee on Heritable and Congenital Disorders to add SMA to Minnesota’s newborn screening panel. With this decision, Minnesota becomes the second state, after Missouri, to adopt permanent newborn screening for SMA. Cure SMA will also be working with an implementation

Minnesota Becomes Second State to Adopt Newborn Screening for SMA Read More »

Cure SMA Announces Funding for Care Centers Across the US

Leave a Comment / Front Page News, Research, Support & Care /

Cure SMA is pleased to announce the first grants from $450,000 in funding to help increase capacity at SMA treatment sites across the US. In order to increase the number of affected individuals that sites can follow, treat and evaluate, Cure SMA will award $50,000 grants to nine sites, for a total of $450,000 in

Cure SMA Announces Funding for Care Centers Across the US Read More »

Biogen and Ionis Enter Into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy

Leave a Comment / Front Page News, Our Impact, Research /

Biogen and Ionis Pharmaceuticals announced that they have entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy (SMA). Biogen will have the option to license therapies arising out of this collaboration and will be responsible for their development and commercialization. “We are pleased to

Biogen and Ionis Enter Into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy Read More »

Cure SMA Assists Hundreds of Families in 2017

Leave a Comment / Front Page News, Our Impact, Support & Care /

Each year, Cure SMA provides thousands of families with vital support and resources to help them live active, engaged and hopeful lives. Our programs provide tangible support for families affected by SMA, easing the difficulties of an SMA diagnosis, and showing each family that they are not alone and that there is hope. Our family

Cure SMA Assists Hundreds of Families in 2017 Read More »

Scroll to Top